GlassScriptPhysician profile
Alexander Masters
NPI 1750775813
$12,492.69
in general payments reported to CMS, 2019-2025
34 companies · $3,316 in 2025
The $3,316 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,266 · 2022: $1,659 · 2023: $2,677 · 2024: $2,574 · 2025: $3,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,501 · Education: $66.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,500.64 |
| Education | $66.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,823.55 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,541.96 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,173.46 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $841.30 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $704.26 | 2021-2025 | Tremfya, Stelara, Remicade |
| Daiichi Sankyo INC. | $514.98 | 2021-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $390.76 | 2021-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $385.46 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $261.06 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $256.21 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $252.93 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $238.20 | 2021-2024 | Dificid, Recarbrio, Zerbaxa |
| Ardelyx, INC. | $232.66 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $209.80 | 2024-2025 | Dupixent |
| Genzyme Corporation | $209.39 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200.22 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $159.47 | 2021-2023 | |
| Celgene Corporation | $156.21 | 2022-2023 | Zeposia |
| Medtronic, INC. | $134.62 | 2023 | Interstim |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | |
| Madrigal Pharmaceuticals | $119.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $108.32 | 2025 | Omvoh |
| Pfizer INC. | $86.69 | 2024-2025 | |
| Vivus LLC | $69.33 | 2025 | Qsymia |
| Aimmune Therapeutics, INC. | $52.41 | 2025 | Zenpep, Vowst |
| Celltrion USA INC. | $42.94 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $37.34 | 2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $30.50 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $30.40 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $27.72 | 2021-2022 | |
| Sandoz INC. | $24.00 | 2023 | Hyrimoz |
| Phadia US INC. | $18.62 | 2025 | Immunocap |
| Alfasigma USA, INC. | $17.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.